VitaSpring Biomedical Co earned $0.00 per diluted share in fiscal year 2026. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2026 through Q2 FY2027, the same line adds up to $0.00 per diluted share. The table below carries 10 fiscal years, from 2017 to 2026, and the quarters VitaSpring Biomedical Co has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
VitaSpring Biomedical Co earned $0.00 per diluted share in fiscal year 2026.
VitaSpring Biomedical Co (VSBC) reported $0.00 per diluted share in fiscal year 2025 and $0.00 per diluted share in fiscal year 2026. A growth rate is not meaningful here, because the earlier figure was zero or negative.
VitaSpring Biomedical Co (VSBC) reported $0.00 per diluted share over the trailing 12 months, Q3 FY2026 through Q2 FY2027, summed from the four most recent quarterly filings.
Across the 10 fiscal years this page covers, VitaSpring Biomedical Co (VSBC) diluted earnings per share went from $0.00 in fiscal year 2017 to $0.00 in fiscal year 2026.
VitaSpring Biomedical Co (VSBC) reported $0.00 in diluted earnings per share in Q2 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what VitaSpring Biomedical Co (VSBC) reported on that line in every period on record.
